NCT01149369View on ClinicalTrials.gov

Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

September 30, 2015

Conditions
Gastroparesis
Interventions
DRUG

Aprepitant

Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks

DRUG

Placebo

Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks

Trial Locations (8)

19140

Temple University Hospital, Philadelphia

21224

Johns Hopkins Bayview Medical Center, Baltimore

27157

Wake Forest University Health Sciences, Winston-Salem

40202

University of Louisville, Louisville

48109

University of Michigan Medical Center, Ann Arbor

79905

Texas Tech University Health Sciences Center, El Paso

94115

California Pacific Medical Center, San Francisco

94305-5187

Stanford University, Stanford

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT01149369 - Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial | Biotech Hunter | Biotech Hunter